ENPICOM announces funding to scale operations for antibody d...| MENAFN.COM

Saturday, 22 January 2022 06:42 GMT

ENPICOM announces funding to scale operations for antibody discovery SaaS platform

(MENAFN- Market Press Release) January 13, 2022 5:49 pm - BOP Capital leads investment round supported by ENPICOM's existing investors

ENPICOM, an innovative bioinformatics software engineering company, today announced the closing of a capital investment round led by BOP Capital. With this additional growth capital, the company can support the rapidly expanding customer base for its unique SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. ENPICOM saw a rapid market uptake of its Antibody Discovery Module by Pharma, Biotech and CRO's after launch in early 2021. The additional funds enable the company to scale at a faster pace in this highly attractive market and continuing to deliver innovative product extensions for improved antibody discovery, characterization, and development.

ENPICOM's IGX Platform is a powerful cloud solution designed to improve immunogenomics research by guiding the discovery and development of superior biotherapeutics. Tailored to the needs of scientists working in antibody discovery, it offers an intuitive environment to combine and manage sequencing data derived from state-of-the-art sequencing technologies (e.g., Sanger, bulk NGS, and Single Cell), integrate assay data from wet-lab experiments, and predict exposed sequence liabilities. All this information can be incorporated into tailored analysis workflows to support candidate selection and prioritization, and significantly improve efficiency and costs of early-stage R&D.

“We are thrilled with this capital injection to further grow our business. It clearly illustrates the trust of our existing investor group, BOM Brabant Ventures, NextGen Ventures, and Arches Capital, in our team and proposition. With the addition of BOP Capital, we have a great new strategic investor on board.' said Jos Lunenberg, Chief Executive Officer at ENPICOM.

“BOP Capital is very proud to join ENPICOM's investor base. We believe in impact through technology. This is exactly what we see in ENPICOM's platform. In combination with exceptional leadership and a strong execution track record, this provides a perfect setup to realize future growth in a highly promising market. We are looking forward to becoming part of their journey and work closely with the Enpicom team in the coming years.” said Jeroen Mensen, Managing Partner at BOP Capital.

ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of over 25 experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system, to biotech and global pharmaceutical companies focusing on the discovery and development of novel immunotherapies and vaccines.
Leveraging a unique mix of immunology knowledge, bioinformatics method development, and software engineering skills, ENPICOM offers a world-class repertoire sequencing data analysis solution – the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors.
For more information, visit enpicom.com and follow us on LinkedIn.

About BOP Capital
BOP Capital is a multidisciplinary venture fund focused on investing alongside entrepreneurs, scientists and management teams operating companies with a strong focus on innovation and impact; supporting the transition of society towards a more sustainable and socially responsible environment through challenging the status quo. While we remain sector agnostic, our portfolio companies mainly operate in the broader definition of the technology and life science industry. We have an active network of experts in various sub sectors to support us during due diligence and the partnership with our portfolio companies.

About Brabant Development Agency
The Brabant Development Agency (BOM) is an economic development company that is committed to enable companies in Brabant to grow their business. Together with a network of partners, BOM provides knowledge, capital, talent, market and facilities to companies with growth ambitions and growth potential. These companies devise solutions to economic and social issues. In this way BOM contributes to an innovative and resilient Brabant economy. For more information, please visit Arches Capital
Arches Capital, a fast-growing group of business angels, invests in startup and scaleup companies with a large growth potential. Through its investments, Arches Capital bridges the gap between formal investors (VCs) and informal investors (business angels), by joining the best of both worlds:
'We source, select and invest like a VC; We engage, care and inspire as the angel we are.'
By bundling smart capital (combining funding with real business knowledge and experience) with true engagement (actively working together to achieve growth), we are able to ignite early-stage companies achieve above-average growth. Arches Capital distinguishes itself from other angel networks by its active support to angels building a broad and professional investment portfolio, co-investment from Arches Capital in each deal and the unique distribution of proceeds amongst its members. For more information visit: NextGen Ventures
Nextgen Ventures is an investment fund investing in knowledge-intensive companies that enable transformation in health care. We actively work with our portfolio companies to develop and market potential breakthrough innovations in health care IT and medical technology that provide meaningful results for people, patients, and professionals.
For more information, visit For more information:


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.